f-star GmbH, a Vienna, Austria-based biopharmaceutical company developing a new generation of antibody based products, closed a €15m financing.
The round was led by SR One, with participation from existing investors Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management.
This brings the total amount raised by the company to date to 34.0m.
In conjunction with the funding, SR One Partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star’s Supervisory Board.
The company intends to use the funds to progress its product candidates into development and maximise the potential of its Modular Antibody Technology platform.
Founded in 2006 and led by CEO Dr Kevin FitzGerald, f-star has 23 employees at its research sites in Vienna, Austria and Cambridge, UK.